WinHealth Pharma

Explore the latest insights on WinHealth Pharma and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of WinHealth Pharma’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Deals

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma") announced the completion of a Series A financing round raising nearly RMB 400 million, capital that will be primarily deployed to advance the…

November 12, 2026

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

November 12, 2026

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

November 12, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Drug

WinHealth Pharma

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

Empowering Chinese Pharma’s Global Expansion

CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti

WinHealth Pharma and Ferring Partner to Co-Promote Pentasa in China

Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China

About Company